Publications by authors named "S Antolin"
Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study.
J Nutr Health Aging
August 2024
Article Synopsis
- - The study investigates how following cancer prevention guidelines from the WCRF/AICR affects the health-related quality of life (HRQL) in breast cancer survivors over a long period, specifically comparing their status at diagnosis and 7-12 years later.
- - Researchers analyzed data from 406 breast cancer survivors, collecting information on lifestyle, diet, physical activity, and HRQL using a scoring system based on WCRF/AICR recommendations.
- - Results indicate that higher adherence to these cancer prevention guidelines is linked to slight improvements in the physical aspect of HRQL over time, while no significant change was found in the mental HRQL domain.
KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
Semin Arthritis Rheum
April 2024
Background: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with systemic sclerosis (SSc). Serum biomarkers have been suggested as indicators for pulmonary damage with clinical value in the diagnosis and prognosis of SSc-ILD.
Objectives: To investigate the role of serum biomarkers (Krebs von den Lungen-6 KL-6, IL-18 and IL-18BP) as a potential biomarker reflecting the severity of SSc-ILD as assessed through high-resolution computed tomography (HRCT) and pulmonary function tests (PFT), including forced vital capacity (%FVC) and diffusing capacity of the lung for carbon monoxide (%DLCO).
Article Synopsis
- The DESTINY-Breast03 trial compared the efficacy and safety of two treatments for HER2-positive metastatic breast cancer: trastuzumab deruxtecan and trastuzumab emtansine.
- Patients aged 18 or older with previously treated HER2-positive breast cancer were randomly assigned to receive one of the treatments.
- The trial showed an improvement in progression-free survival for trastuzumab deruxtecan compared to trastuzumab emtansine, and the study is ongoing with results registered on ClinicalTrials.gov.
Background: We aimed to determine the effect of dual anti-HER2 blockade compared to monotherapy on clinically important outcomes.
Methods: We carried out a systematic review updated until July 2022. The outcomes included pathological complete response (pCR), clinical response, event-free survival, and overall survival.
Breast cancer (BC) survivors are advised to follow the WCRF/AICR cancer prevention recommendations, given their high risk of developing a second tumour. We aimed to explore compliance with these recommendations in BC survivors and to identify potentially associated clinical and sociodemographic factors. A total of 420 BC survivors, aged 31-80, was recruited from 16 Spanish hospitals.
View Article and Find Full Text PDF